NOVEL IMMUNOTHERAPIES (CAR-T, BiTE)

Data from an analysis of 52 children and young adults with hematologic malignancies who received CD19 CAR T-cell therapy suggests that implementation of more frequent monitoring, using echocardiograms with systemic analysis of changes in global longitudinal strain and cardiac biomarkers troponin and proBNP, may help clinicians identify patients at high risk of severe cardiac systolic dysfunction earlier and therefore facilitate earlier interventions for cytokine release syndrome.